168 related articles for article (PubMed ID: 25554218)
1. ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.
Moody TW; Mantey SA; Moreno P; Nakamura T; Lacivita E; Leopoldo M; Jensen RT
Peptides; 2015 Feb; 64():55-61. PubMed ID: 25554218
[TBL] [Abstract][Full Text] [Related]
2. Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.
Moody TW; Sancho V; di Florio A; Nuche-Berenguer B; Mantey S; Jensen RT
Peptides; 2011 Aug; 32(8):1677-84. PubMed ID: 21712056
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells.
Moody TW; Leyton J; Garcia-Marin L; Jensen RT
Eur J Pharmacol; 2003 Aug; 474(1):21-9. PubMed ID: 12909192
[TBL] [Abstract][Full Text] [Related]
4. Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.
Moody TW; Pradhan T; Mantey SA; Jensen RT; Dyba M; Moody D; Tarasova NI; Michejda CJ
Life Sci; 2008 Apr; 82(15-16):855-61. PubMed ID: 18336841
[TBL] [Abstract][Full Text] [Related]
5. Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3.
Ryan RR; Weber HC; Hou W; Sainz E; Mantey SA; Battey JF; Coy DH; Jensen RT
J Biol Chem; 1998 May; 273(22):13613-24. PubMed ID: 9593699
[TBL] [Abstract][Full Text] [Related]
6. AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.
Moody TW; Tashakkori N; Mantey SA; Moreno P; Ramos-Alvarez I; Leopoldo M; Jensen RT
Front Endocrinol (Lausanne); 2017; 8():176. PubMed ID: 28785244
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells.
Moody TW; Jensen RT; Garcia L; Leyton J
Eur J Pharmacol; 2000 Dec; 409(2):133-42. PubMed ID: 11104826
[TBL] [Abstract][Full Text] [Related]
8. A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.
Moreno P; Mantey SA; Lee SH; Ramos-Álvarez I; Moody TW; Jensen RT
Peptides; 2018 Mar; 101():213-226. PubMed ID: 29410320
[TBL] [Abstract][Full Text] [Related]
9. Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
Moody TW; Nakagawa T; Kang Y; Jakowlew S; Chan D; Jensen RT
J Mol Neurosci; 2006; 28(3):231-8. PubMed ID: 16691010
[TBL] [Abstract][Full Text] [Related]
10. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.
Sancho V; Moody TW; Mantey SA; Di Florio A; Uehara H; Coy DH; Jensen RT
Peptides; 2010 Aug; 31(8):1569-78. PubMed ID: 20438784
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors.
Moreno P; Mantey SA; Nuche-Berenguer B; Reitman ML; González N; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2013 Oct; 347(1):100-16. PubMed ID: 23892571
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.
Gonzalez N; Hocart SJ; Portal-Nuñez S; Mantey SA; Nakagawa T; Zudaire E; Coy DH; Jensen RT
J Pharmacol Exp Ther; 2008 Feb; 324(2):463-74. PubMed ID: 18006692
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368.
Tokita K; Hocart SJ; Katsuno T; Mantey SA; Coy DH; Jensen RT
J Biol Chem; 2001 Jan; 276(1):495-504. PubMed ID: 11013243
[TBL] [Abstract][Full Text] [Related]
15. Four amino acid residues are critical for high affinity binding of neuromedin B to the neuromedin B receptor.
Sainz E; Akeson M; Mantey SA; Jensen RT; Battey JF
J Biol Chem; 1998 Jun; 273(26):15927-32. PubMed ID: 9632639
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.
Ryan RR; Katsuno T; Mantey SA; Pradhan TK; Weber HC; Coy DH; Battey JF; Jensen RT
J Pharmacol Exp Ther; 1999 Sep; 290(3):1202-11. PubMed ID: 10454496
[TBL] [Abstract][Full Text] [Related]
17. A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells.
Weber HC; Walters J; Leyton J; Casibang M; Purdom S; Jensen RT; Coy DH; Ellis C; Clark G; Moody TW
Eur J Pharmacol; 2001 Jan; 412(1):13-20. PubMed ID: 11166731
[TBL] [Abstract][Full Text] [Related]
18. CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Moody TW; Nuche-Berenguer B; Moreno P; Jensen RT
J Mol Neurosci; 2015 Jul; 56(3):663-72. PubMed ID: 25761747
[TBL] [Abstract][Full Text] [Related]
19. Systematic optimization of a lead-structure identities for a selective short peptide agonist for the human orphan receptor BRS-3.
Weber D; Berger C; Heinrich T; Eickelmann P; Antel J; Kessler H
J Pept Sci; 2002 Aug; 8(8):461-75. PubMed ID: 12212809
[TBL] [Abstract][Full Text] [Related]
20. Discovery of high affinity bombesin receptor subtype 3 agonists.
Wu JM; Nitecki DE; Biancalana S; Feldman RI
Mol Pharmacol; 1996 Nov; 50(5):1355-63. PubMed ID: 8913368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
